Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.33 |
| ▸ | PITRM1 | Q5JRX3 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8277385 | 0.98 | TSHR (0.33) | ALDH1A1SMN1; SMN2DPP4FAPPITRM1 | |
| SCHEMBL8277960 | 0.81 | CYP2C19 (0.41) | ALDH1A1SMN1; SMN2DPP4FAPPITRM1 | |
| SCHEMBL8277249 | 0.78 | TSHR (0.42) | DPP4FAPPITRM1DPP8DPP9 | |
| SCHEMBL13201634 | 0.77 | DPP4 (0.31) | DPP4FAPPITRM1DPP8DPP9 | |
| SCHEMBL13201636 | 0.74 | TSHR (0.31) | TSHRNFKB1CYP2C19 | |
| SCHEMBL13640446 | 0.73 | TSHR (0.47) | TSHRNFKB1CYP2C19 | |
| SCHEMBL14899074 | 0.73 | CYP2C19 (0.34) | ALDH1A1SMN1; SMN2DPP4FAPPITRM1 | |
| SCHEMBL13463608 | 0.71 | EPHX1 (0.32) | — | |
| SCHEMBL14899073 | 0.71 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2DPP4FAPPITRM1 | |
| SCHEMBL18789723 | 0.71 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2DPP4FAPPITRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| WO-2006007700-A1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | ALDH1A1 1136/4885SMN1; SMN2 4344/4885DPP4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.